ATM Kinase Inhibitor Compounds for Potency and Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current ATM kinase inhibitors lack potency, selectivity, and safety for use in cancer treatment, with no approved drugs available despite decades of research.

Innovation Solution

Development of compounds with general formula (Ia) or (Ib) that inhibit, regulate, and modulate ATM kinase, offering high potency, selectivity, and low toxicity, suitable for treating various cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current ATM kinase inhibitors are used, then ATM kinase inhibition is achieved, but potency and selectivity are insufficient

Engineering Contradiction:

Improveinhibition efficacyVSAvoidlack of potency and selectivity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of ATM kinase inhibitors through specific substituent patterns (R1-R6 groups) and ring configurations to enhance both potency and selectivity. The general formula (I) with variable substituents allows optimization of binding affinity and specificity parameters to overcome the limitations of existing inhibitors.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements local quality by introducing specific functional groups at particular positions (R1-R6 substituents) on the core structure to achieve localized interactions with the ATM kinase binding site. This allows different regions of the molecule to contribute differently to potency and selectivity, addressing the insufficient discrimination of current inhibitors.

Inventive Principle:

Principle #3Local quality

2Reliability

If current ATM kinase inhibitors are developed, then therapeutic potential is achieved, but safety profile is inadequate

Engineering Contradiction:

Improvetherapeutic potentialVSAvoidtoxicity to humans and animals

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies safety parameters by optimizing the chemical structure through controlled substitution patterns and molecular weight considerations. The general formula (I) with defined substituent options (halogens, alkyl groups, heterocycles) allows tuning of pharmacokinetic and toxicological parameters to improve the therapeutic index while maintaining efficacy.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If no approved ATM kinase inhibitors are available, then research opportunities exist, but clinical treatment options are limited

Engineering Contradiction:

Improveresearch potentialVSAvoidlack of treatment options

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The patent creates a universal inhibitor platform with general formula (I) that can target ATM kinase across multiple cancer types and disease states. The versatile substituent options allow the same core structure to be adapted for different therapeutic indications, providing both research utility and potential clinical applicability where no approved treatments exist.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260015328A1ATM kinase inhibitors

Publication Date: 2026.01.15 EBERHARD KARLS UNIVERSITAET TUEBINGEN

AI summary

The present invention discloses compounds of the general formula (Ia) or (Ib):pharmaceutical compositions comprising said compounds and their use in the treatment of diseases, particularly cancers. In addition, method for treating a disease in which mediation, such as inhibition, regulation and/or modulation, of ATM kinase is beneficial in a human or a warm-blooded or mammal animal in need of such treatment is disclosed.